The class started 19.10.2017. 10 years does not exist yet; the figure above is since launch, annualised (as of 13.11.2026).
Calculated NOK return from USD · EUR Acc (NOK Calculated)
Computed from NAV history (to 13 Nov 2026)
Last NAV 10,51 USD · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+20,0 %
YTD
+25,3 %
1y
+19,0 %
3y, annualised
+10,7 %
5y, annualised
Fund size
1,4 mrd. USD
Total fund AUM
Ongoing charge
0,35 %
Annual · class EUR Acc
Performance fee
None
Stated by the manager
Annual cost on platforms
0,41 %
Class EUR Acc · 1 platform · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Other
Sustainability
Launched
Oct 2017
ISIN IE00BYXG2H39
BenchmarkNasdaq Biotechnology · Net
Risk
Volatility (stated by the manager)16,7 %
Beta1,00
About the fund
The fund
iShares NASDAQ US Biotechnology UCITS ETF is an exchange-traded index fund with a track record back to 2017. It aims to follow the NASDAQ Biotechnology Index, which consists of biotechnology and pharmaceutical companies listed on NASDAQ. The management company is BlackRock, a global asset manager founded in 1988 and headquartered in New York. BlackRock is publicly listed with dispersed ownership and owns the iShares ETF brand.
Investment philosophy
The fund is passive: the portfolio is governed by the index rules, not by individual choices made by managers. The universe is limited to companies listed on NASDAQ.
The managers
The fund is index-managed by BlackRock and follows the index rather than a named portfolio manager.
The portfolio
The portfolio is broad in the number of companies, but the top carries a heavy weight. Companies such as Amgen, Vertex Pharmaceuticals, Gilead Sciences and Regeneron Pharmaceuticals recur among the top positions.
FundTelligence description · 18/10/2026
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
Portfolio managers
Managed by a team: BlackRock Asset Management Ireland Limited
Industry Biotechnology Equities · 6 funds in the peer group. The number ranked and the date are stated per period. 3 of them converted to NOK.
2 of 4 funds ranked on a calculated return
#1/ 4Year to date
+19.99% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#2/ 41 year
+25.28% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#2/ 43 years (ann.)
+18.95% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#2/ 45 years (ann.)
+10.75% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
Comparison basis
Year to date
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
1 year
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
3 years (ann.)
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
5 years (ann.)
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.